The biowaiver procedure: Its application to antituberculosis products in the WHO prequalification programme

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 822-830

  Strauch, Stefanie ^a   Jantratid, Ekarat ^a,c   Stahl, Matthias ^b   Rägo, Lembit ^b   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Bioavailability; Bioequivalence; Biopharmaceutics classification system; Dissolution; Ethambutol; Isoniazid; Pharmacokinetics; Pyrazinamide; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; WORLD HEALTH ORGANIZATION;

EID: 79251586870     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22349     Document Type: Article

References (22)

1. World Health Organization. 2008. Stop TB partnership: 2008 tuberculosis facts. Accessed September 2010, at.
2. World Health Organization. 2008. WHO report 2008: Global tuberculosis control-surveillance, planning, financing. Accessed September 2010, at.
3. World Health Organization. 2008. Prequalification programme. Accessed September 2010, at.
4. World Health Organization. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. WHO Technical Report Series No 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Accessed September 2010, at.
5. US, Department of Health and Human Services, Food and Drug Administration, Center for Evaluation and Research (CDER). 2000 Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Accessed September 2010, at.
6. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
7. World Health Organization. 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. WHO Technical Report Series No 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. Accessed September 2010, at.
8. US Department of Health and Human Services, Food and Drug Administration, Center for Evaluation and Research (CDER). Guidance for Industry: Immediate release solid oral dosage forms scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. Accessed September 2010, at.
9. World Health Organization Department of Essential Medicines and Pharmaceutical Policies (EMP). 2006. Isoniazid and ethambutol hydrochloride tablets. In: The International Pharmacopoeia, 4th ed. Accessed September 2010, at.
10. European Medicines Evaluation Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. Accessed September 2010, at.
11. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride. J Pharm Sci 97(4):1350-1360.
12. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System. Eur J Pharm Biopharm 58(2):265-278.
13. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1(1):85-96.
14. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid. J Pharm Sci 96(3):522-531.
15. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide. J Pharm Sci 97(9):3709-3720.
16. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15(1):11-22.
17. World Health Organization. Prequalification of Medicines Programme. 2009. Recommended comparator products: Anti-tuberculosis medicines. Accessed September 2010, at.
18. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2003. Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Accessed September 2010, at.
19. Midha KK, Rawson MJ, Hubbard JW. 1997. Individual and average bioequivalence of highly variable drugs and drug products. J Pharm Sci 86(11):1193-1197.
20. Midha KK, Rawson MJ, Hubbard JW. 2005. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther 43(10):485-498.
21. Balthasar JP. 1999. Bioequivalence and bioequivalency testing. Am J Pharm Educ 63:194-198.
22. Polli JE. 2008. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms. AAPS J 10(2):289-299.